title: Cancer cell metabolism as new targets for novel designed therapies.
abstract: Metabolic processes are altered in cancer cells, which obtain advantages from this metabolic reprogramming in terms of energy production and synthesis of biomolecules that sustain their uncontrolled proliferation. Due to the conceptual progresses in the last decade, metabolic reprogramming was recently included as one of the new hallmarks of cancer. The advent of high-throughput technologies to amass an abundance of omic data, together with the development of new computational methods that allow the integration and analysis of omic data by using genome-scale reconstructions of human metabolism, have increased and accelerated the discovery and development of anticancer drugs and tumor-specific metabolic biomarkers. Here we review and discuss the latest advances in the context of metabolic reprogramming and the future in cancer research.
authors.affiliation: Department of Biochemistry & Molecular Biology, Faculty of Biology, IBUB, Universitat de Barcelona & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Unit Associated with CSIC, Diagonal 643, E-08028-Barcelona, Spain.
authors.forename: Igor
authors.initials: I
authors.lastname: Marín de Mas
authors.forename: Esther
authors.initials: E
authors.lastname: Aguilar
authors.forename: Anusha
authors.initials: A
authors.lastname: Jayaraman
authors.forename: Ibrahim H
authors.initials: IH
authors.lastname: Polat
authors.forename: Alfonso
authors.initials: A
authors.lastname: Martín-Bernabé
authors.forename: Rohit
authors.initials: R
authors.lastname: Bharat
authors.forename: Carles
authors.initials: C
authors.lastname: Foguet
authors.forename: Enric
authors.initials: E
authors.lastname: Milà
authors.forename: Balázs
authors.initials: B
authors.lastname: Papp
authors.forename: Josep J
authors.initials: JJ
authors.lastname: Centelles
authors.forename: Marta
authors.initials: M
authors.lastname: Cascante
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D019295:Computational Biology; D015195:Drug Design; D057166:High-Throughput Screening Assays; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor